The stock of InflaRx N.V. (NASDAQ:IFRX) is a huge mover today! The stock decreased 2.71% or $0.075 during the last trading session, reaching $2.695. About 356,787 shares traded. InflaRx N.V. (NASDAQ:IFRX) has declined 90.11% since August 6, 2018 and is downtrending. It has underperformed by 90.11% the S&P500.
The move comes after 8 months negative chart setup for the $69.97M company. It was reported on Aug, 6 by Barchart.com. We have $2.56 PT which if reached, will make NASDAQ:IFRX worth $3.50M less.
Analysts await InflaRx N.V. (NASDAQ:IFRX) to report earnings on August, 8. They expect $-0.55 earnings per share, down 358.33 % or $0.43 from last year’s $-0.12 per share. After $-0.43 actual earnings per share reported by InflaRx N.V. for the previous quarter, Wall Street now forecasts 27.91 % negative EPS growth.
More notable recent InflaRx N.V. (NASDAQ:IFRX) news were published by: Globenewswire.com which released: “InflaRx Continues U.S. Expansion with Addition of New York City Corporate Office and Addition of Management – GlobeNewswire” on January 03, 2019, also Globenewswire.com with their article: “InflaRx Full Year 2018 Financial & Operating Results – GlobeNewswire” published on March 28, 2019, Benzinga.com published: “35 Stocks Moving In Monday’s Pre-Market Session – Benzinga” on July 22, 2019. More interesting news about InflaRx N.V. (NASDAQ:IFRX) were released by: Benzinga.com and their article: “InflaRx (NASDAQ:IFRX) Shares Slammed As Skin Inflammation Drug Flunks Midstage Trial; ChemoCentryx (NASDAQ:CCXI) Moves In Sympathy – Benzinga” published on June 05, 2019 as well as Globenewswire.com‘s news article titled: “InflaRx Announces Presentation of New Clinical Data with Lead Candidate IFX-1 in Hidradenitis Suppurativa – GlobeNewswire” with publication date: February 06, 2019.
InflaRx GmbH, a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology in the United States. The company has market cap of $69.97 million. The Company’s C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. It currently has negative earnings. The firm is involved developing IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and other chronic/autoimmune diseases, as well as IFX-2 for the treatment of chronic inflammation and autoimmune diseases.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.